PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC), announced today that its collaboration partner, the Drugs for Neglected Diseases initiative (DNDi), has commenced Phase 1 clinical studies of SCYX-7158 (also referred to as AN5568), the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness. AN5568 was discovered utilizing Anacor’s boron-based chemistry and is Anacor’s sixth compound to enter human clinical development since the company was started ten years ago.
